Innovative Peptide Solutions



SARS-CoV-2 Peptide Tools

Full virus genome coverage for

- **Cellular Immunity Assessment**
- **Peptide Resolved Antibody Profiling**
- **T- & B-Cell Epitope Identification**
- **Clinical Trial Immune Monitoring**

Contact us for further information: peptide@jpt.com

JPT Peptide Technologies
www.jpt.com
peptide@jpt.com

Contact
T +49-30-6392-7878
F +49-30-6392-7888

USA/Canada
T 1-888-578-2660
F 1-888-578-2666

jpt
Innovative Peptide Solutions

T-Cell Immunity

PepMix™ Peptide Pools

All SARS-CoV-2 antigens, frequent mutations & relevant antigens of other coronaviruses, e.g. HCoV 229E, HKU1, OC43 & NL63, represented as overlapping peptide pools for antigen-specific stimulation T-cells

Check all SARS-CoV-2 PepMixes™

Epitope Mapping Peptide Sets

Sets of matrix pools & individual peptides available for relevant SARS-CoV-2 and common cold antigens for cross-reactivity and immunity studies, T-cell epitope identification & blood test development

Learn more

Antigen Peptides

Wide variety of SARS-CoV-2 epitopes as individual antigen peptides for stimulation of T-cells with specific epitopes

Search SARS-CoV-2 Antigen Peptides

Custom Peptide Synthesis

Clinical and research grade peptide synthesis with specifications tailored to your application and needs, e.g. for clinical trial immune monitoring and cell therapy & vaccine development

Clinical-Grade Peptides

Research-Grade Peptides





B-Cell Immunity

RepliTope™ Peptide Microarrays

Pan-Coronavirus Peptide Microarray (whole genome of SARS-CoV-2 & SARS-CoV, MERS, HCoV antigens) & Multiwell Peptide Microarrays for individual antigens for antibody epitope discovery and antibody test development

Read more

Antibody Response Profiling

Peptide Microarray and ELISA assay services for serology testing & antibody epitope discovery with RepliTope™ Microarrays or customized PepStar™ Microarrays and Peptide ELISA

Learn more

Proteomics

SpikeMix™ Peptide Standards

Stable isotope labeled peptide references for SARS-CoV-2 antigens used in mass spec assays, e.g. multiplexed analysis and relative quantification of SARS-CoV-2 antigens in biological samples

Check SARS-CoV-2 SpikeMix

Catalog Products	Coronavirus PepMix™ Peptide Pools SARS-CoV-2 Epitope Mapping Peptide Sets (EMPS) COVID-19 Antigen Peptides	RepliTope™ Pan-Coronavirus Peptide Microarray SARS-CoV-2 Multiwell Microrrays	SpikeMix™ SARS-CoV-2
Services	Research-Grade Peptides Clinical-Grade Peptides	PepStar ™ Peptide Miroarrays Peptide ELISA Antibody Response Profiling	Reference Peptides SpikeTides™ Absolutely Quantified SpikeTides TQL

Summary of SARS-CoV-2 Peptide Tools & Services

Selected References

- *"Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors"*
  Braun et al, Nature (2020)
- *"SARS-CoV-2 infection protects against rechallenge in rhesus macaques"*
  Chandrashekar et al, Science (2020)
- *"SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness"*
  Corbett et al, bioRxiv (2020)
- *"Data, reagents, assays and merits of proteomics for SARS-CoV-2 research and testing"*
  Zecha et al, Mol Cell Proteomics (2020)
- *"A longitudinal study of immune cells in severe COVID-19 patients"*
  Payen et al, medRXiv (2020)
- *"SARS-CoV-2-specific T cells exhibit unique features characterized by robust helper function, lack of terminal differentiation, and high proliferative potential"*
  Neidleman et al, bioRxiv (2020)
- *"Generation of SARS-CoV-2 S1 spike glycoprotein putative antigenic epitopes in vitro by intracellular aminopeptidases"*
  Stamatakis et al bioRxiv (2020)
- *"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice"*
  McKay et al, Nature 2020
- *"An mRNA Vaccine against SARS-CoV-2 – Preliminary Report"*
  Jackson et al, New England J of Med (2020)
- *"SARS-CoV-2-reactive interferon-γ-producing CD8+ T cells in patients hospitalized with Coronavirus Disease 2019"*
  Giminez et al, J Med Vir (2020)
- *"Concurrent human antibody and TH1 type T-cell responses 2 elicited by a COVID-19 RNA vaccine"*
  Sahin et al, medRXiv (2020)

Issue Date: July 2020

JPT Peptide Technologies
www.jpt.com
peptide@jpt.com

Contact
T +49-30-6392-7878
F +49-30-6392-7888

USA/Canada
T 1-888-578-2660
F 1-888-578-2666

jpt
Innovative Peptide Solutions